logo
More than one in four couples in India are overweight or obese: ICMR study

More than one in four couples in India are overweight or obese: ICMR study

India Today2 days ago
A new study from the Indian Council of Medical Research (ICMR), the country's top medical panel, has revealed rising obesity levels among married couples in India, highlighting that more than one in four couples (27.4%) are both overweight or obese.Based on data from over 52,737 married couples as part of the NFHS-5 (2019–21), this is one of the largest investigations of spousal weight trends conducted in the country.advertisementThe study, led by ICMR-National Institute of Cancer Prevention and Research, draws attention to what experts are calling "spousal concordance" in obesity, a situation where both partners mirror each other's unhealthy weight status.
A SHARED JOURNEY TO WEIGHT GAINThe findings, published in Current Developments in Nutrition, suggest that couples are unknowingly reinforcing each other's unhealthy habits.Whether it's shared meals high in calories, late-night snacking, sedentary routines, or bonding over food, lifestyle choices often become aligned in a marriage.'From what we eat to how much we move, partners tend to mimic each other's behaviours,' noted the ICMR team.Young, urban couples appear to be most affected.The study found that 27.4% of married couples in India are both overweight or obese. This means that more than one in four couples share a similar weight status, which is often the result of shared habits and lifestyle choices.This trend was seen more commonly among wealthier couples, especially those in the richest income group, where nearly 47.6% of couples were overweight or obese. Couples living in urban areas also showed a high rate of weight gain together, with 38.4% of city-based couples affected.The numbers were higher among couples living in nuclear families (28.9%) and those who were of similar age (28.8%) or had the same level of education (31.4%). Couples who were not doing paid work also showed a higher chance of being overweight together (33.9%).Media habits also seemed to play a role. Couples who regularly read newspapers (39.6%) or watched television (32.8%) had a higher risk of shared obesity. Similarly, eating habits mattered too, couples who ate non-vegetarian food like eggs (30.7%) and chicken (29.9%) every week were more likely to be overweight or obese.Geographically, the highest rates of overweight couples were found in the southern (37.2%) and northern (33.5%) parts of the country. States like Kerala, Jammu and Kashmir, Manipur, Delhi, Goa, Tamil Nadu, and Punjab had the highest rates—more than 42% of couples in these states were overweight or obese.The researchers also found that some groups had a significantly higher risk of spousal obesity. These included couples from rich households, those living in urban areas, and those from certain religious groups.advertisementLastly, eating certain foods regularly, such as eggs (14%), fish (25%), chicken (9%), fried foods (6%), and especially alcohol (98%)—was strongly linked to both partners gaining excess weight.MORE THAN JUST LIFESTYLEWhile diet and physical inactivity are major contributors, cultural and economic forces also play a role.Dr. Siri M Kamath, Consultant in Internal Medicine at Gleneagles BGS Hospital, Bengaluru, told IndiaToday.in, that overweight is still often associated with prosperity and good health, especially in older mindsets. 'Being slim is sometimes wrongly viewed as a sign of weakness,' said Dr. Kamath.Economically, staples like rice and wheat are heavily subsidised through the public distribution system, while vegetables and protein-rich pulses remain less accessible.'This makes carbs more affordable and, unfortunately, more dominant in Indian meals,' the expert added.With obesity being a risk factor for Type 2 diabetes, cardiovascular disease, hypertension, infertility, and even certain cancers, the implications go far beyond appearance—they impact India's long-term health and productivity.WHY COUPLE-BASED INTERVENTIONS MATTERThe ICMR researchers recommend a shift in how obesity is tackled in India. Rather than focusing on individuals, interventions should address couples and households, especially those in urban, affluent, and media-exposed environments.advertisement'Spousal concordance in overweight and obesity is strongly influenced by shared socioeconomic status, lifestyle behaviours, and dietary patterns,' the authors wrote. 'Public health strategies should prioritise couple-based interventions, especially among high-risk subgroups.'With over 27.4% of married couples now falling into the overweight or obese category, India must act fast, not just to treat obesity, but to prevent it from becoming a household epidemic.- EndsMust Watch
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Development of indigenous multi-stage Malaria vaccine 'AdFalciVax' is underway
Development of indigenous multi-stage Malaria vaccine 'AdFalciVax' is underway

Economic Times

timean hour ago

  • Economic Times

Development of indigenous multi-stage Malaria vaccine 'AdFalciVax' is underway

The Indian Council of Medical Research (ICMR), through its Regional Medical Research Centre, Bhubaneswar (RMRCBB) and National Institute of Malaria Research (NIMR), in partnership with the Department of Biotechnology-National Institute of Immunology (DBT-NII), is currently developing a novel recombinant chimeric malaria vaccine candidate, named AdFalciVax. ADVERTISEMENT AdFalciVax is the first indigenous recombinant chimeric malaria vaccine specifically designed to target two critical stages of Plasmodium falciparum, the parasite responsible for the most lethal form of malaria. The vaccine aims to protect against human infection while also reducing vector-borne community transmission of the parasite. According to the release, the vaccine has demonstrated excellent efficacy in the preclinical stage of development. Preclinical data suggest that AdFalciVax may have advantages over existing single-stage vaccines, including broader protection by targeting two vulnerable parasite stages, lower risk of immune evasion, potential for better long-term immunity, and extended thermal stability with functionality maintained for over nine months at room is a recombinant multistage vaccine produced in Lactococcus lactis, designed to protect both individual humans and reduce the community transmission represents one of the most advanced malaria vaccine candidates globally, with a rational design targeting two key stages of the parasite. This vaccine consists of a stable and functional recombinant chimaera between antigenic components that promises dual protection. ADVERTISEMENT ICMR intends to license the technology for AdFalciVax to eligible organisations and manufacturers for further development, manufacture, and commercialisation under non-exclusive agreements. This approach aims to enable wider outreach and maximise public health benefits. All collaborations will adhere to ICMR's Intellectual Property Policy. ADVERTISEMENT As an indigenously developed vaccine candidate that fulfils the Make in India mandate, AdFalciVax holds the potential to contribute substantially to malaria eradication by preventing infection and minimising community information is provided for awareness purposes only. The vaccine candidate is in its early research and development phases and is not yet available for any clinical use or commercialisation. ADVERTISEMENT (You can now subscribe to our Economic Times WhatsApp channel)

ICMR invites EoIs for tech transfer to commercialise malaria vaccine
ICMR invites EoIs for tech transfer to commercialise malaria vaccine

Business Standard

time2 hours ago

  • Business Standard

ICMR invites EoIs for tech transfer to commercialise malaria vaccine

The Indian Council of Medical Research (ICMR) has invited expressions of interest (EoI) from eligible companies and manufacturers to undertake the transfer of technology for commercialisation of an indigenous recombinant multi-stage malaria vaccine candidate named AdFalciVax. The vaccine candidate, being developed by ICMR's Regional Medical Research Centre, Bhubaneswar (ICMR-RMRCBB), aims to prevent plasmodium falciparum, a parasite which causes severe and fatal malaria, in humans and minimise its community transmission. According to the EoI, ICMR-RMRCBB will also provide expert guidance and technical support for the production of the vaccine in all phases, effectively accelerating its development and commercialisation. The agreement is proposed to be executed on a non-exclusive basis with single or multiple companies to enable wider outreach of the malaria vaccine for societal benefit and public health use. It added that the development may take at least seven years in four stages with each stage having a six-month buffer time. While ICMR would provide technical support through its team of experienced scientists in study planning and product development, the selected company would be responsible for obtaining all the regulatory approvals, starting from research and development (R&D) for product development to its commercialisation. The Council will also have no financial implications unless otherwise specified, however, its institutes would provide support and facilitation to conduct the R&D and clinical studies of new technology in India. The EoI adds that in case of transfer of technology, ICMR is the sole owner of the said technology, including any underlying Intellectual Properties and commercialisation rights. 'In case of collaboration between ICMR and the company for the joint development of the technology/product, the Background Intellectual Property (BGIP) shall always remain the sole and non-exclusive property of the party generating it,' the EoI said. As part of the agreement, the collaborating company will be required to share technical data with ICMR and participate in all discussions in a professional and mutually agreed-upon manner. 'Subsequent to the execution of the agreement, such companies/manufacturers shall be responsible to pay the royalty at the rate of 2 per cent on net sales, according to the ICMR Guidelines for Technology Development Collaboration,' the medical research body said. According to the World Health Organisation's (WHO) World Malaria Report 2024, India contributes half of all estimated cases in the South East Asia Region, which in turn accounts for 1.5 per cent of the global malaria burden. India currently has access to two WHO-recommended malaria vaccines, Mosquirix and R21/Matrix-M. While the former is manufactured by GlaxoSmithKline (GSK), the latter is manufactured by the Serum Institute of India (SII). Both vaccines are primarily for children in areas with moderate to high malaria transmission. 'Based on preclinical data, AdFalciVax may offer advantages such as broader protection and a lower risk of immune evasion compared to existing single-stage malaria vaccines,' an official in the know said. The pre-clinical validation of the vaccine candidate was conducted in collaboration with the Indian Council of Medical Research-National Institute of Malaria Research, other constituent institutes of ICMR, and the National Institute of Immunology in Delhi, an autonomous research institute of the Department of Biotechnology.

ICMR invites expression of interest for commercial production of advanced malaria vaccine
ICMR invites expression of interest for commercial production of advanced malaria vaccine

The Print

time3 hours ago

  • The Print

ICMR invites expression of interest for commercial production of advanced malaria vaccine

New Delhi, Jul 20 (PTI) The Regional Medical Research Centre in Bhubaneswar under the ICMR has developed an advanced malaria vaccine that can prevent plasmodium falciparum infection in individuals and minimise community transmission. The Indian Council of Medical Research (ICMR), Delhi, has invited expression of interest (EoI) from eligible organisations, companies and manufacturers enthusiastic about the Transfer of Technology for commercial production of 'a recombinant chimeric multi-stage malaria vaccine (AdFalciVax) against plasmodium falciparum'.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store